Cargando…

Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)

Vascular endothelial growth factor receptor 2 (VEGFR-2) binds to VEGFR-A, VEGFR-C and VEGFR-D and participates in the formation of tumor blood vessels, mediates the proliferation of endothelial cells, enhances microvascular permeability, and blocks apoptosis. Blocking or downregulating the signal tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qian, Zheng, Pengwu, Zhu, Wufu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321177/ https://www.ncbi.nlm.nih.gov/pubmed/32521825 http://dx.doi.org/10.3390/molecules25112666

Ejemplares similares

Design, Synthesis, and Biological Evaluation of [1,2,4]triazolo[4,3-a] Pyrazine Derivatives as Novel Dual c-Met/VEGFR-2 Inhibitors
por: Liu, Xiaobo, et al.
Publicado: (2022)

Design, Synthesis and Biological Evaluation of 6,7-Disubstituted-4-phenoxyquinoline Derivatives Bearing Pyridazinone Moiety as c-Met Inhibitors
por: Liu, Xiaobo, et al.
Publicado: (2018)

Discovery of Triazolo-pyridazine/-pyrimidine Derivatives Bearing Aromatic (Heterocycle)-Coupled Azole Units as Class II c-Met Inhibitors
por: Zhang, Qian, et al.
Publicado: (2020)

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors
por: Shaldam, Moataz A., et al.
Publicado: (2023)

Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
por: Shetu, Shaila A., et al.
Publicado: (2022)

Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents
por: Liu, Yu, et al.
Publicado: (2016)

Bioorthogonal Small Molecule Imaging Agents Allow Single-Cell Imaging of MET
por: Kim, Eunha, et al.
Publicado: (2013)

Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors
por: Tu, Yuanbiao, et al.
Publicado: (2018)

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells
por: Piotrowska, Anna, et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors
por: Yu, Lide, et al.
Publicado: (2019)

Recent progress in DNA methyltransferase inhibitors as anticancer agents
por: Zhang, Zhixiong, et al.
Publicado: (2022)

Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers
por: Wang, Caolin, et al.
Publicado: (2018)

Synthesis and Biological Evaluation of Small Molecules as Potential Anticancer Multitarget Agents
por: Pla-López, Alberto, et al.
Publicado: (2022)

Imidazolylpyrrolone‐Based Small Molecules as Anticancer Agents for Renal Cell Carcinoma
por: Sousa, Ana, et al.
Publicado: (2022)

Research Progress in the Modification of Quercetin Leading to Anticancer Agents
por: Massi, Alessandro, et al.
Publicado: (2017)

The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
por: Carvalho, Bruno, et al.
Publicado: (2021)

Potent Small-Molecule Inhibitors Targeting Acetylated Microtubules as Anticancer Agents Against Triple-Negative Breast Cancer
por: Kwon, Ahreum, et al.
Publicado: (2020)

Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors
por: Saleh, Nashwa M., et al.
Publicado: (2020)

Synthesis and Biological Evaluation of Novel 4-Morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine Derivatives Bearing Phenylpyridine/ Phenylpyrimidine-Carboxamides
por: Liu, Huimin, et al.
Publicado: (2016)

Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors
por: Nishio, Makoto, et al.
Publicado: (2022)

Small-Molecule Poly(ADP-ribose) Polymerase and PD-L1 Inhibitor Conjugates as Dual-Action Anticancer Agents
por: Ofori, Samuel, et al.
Publicado: (2019)

Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors
por: Xiong, Hehua, et al.
Publicado: (2019)

Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER
por: Hsu, Jeff, et al.
Publicado: (2023)

Synthesis and Biological Evaluation of Novel 8-Morpholinoimidazo[1,2-a]pyrazine Derivatives Bearing Phenylpyridine/Phenylpyrimidine-Carboxamides
por: Xu, Shan, et al.
Publicado: (2017)

Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
por: Wu, Chunjiang, et al.
Publicado: (2015)

Synthesis and Structure–Activity Relationships of 4-Morpholino-7,8-Dihydro-5H-Thiopyrano[4,3-d]pyrimidine Derivatives Bearing Pyrazoline Scaffold
por: Wang, Qinqin, et al.
Publicado: (2017)

Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety
por: Hu, Xiaohan, et al.
Publicado: (2021)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020)

Anticancer activity of a novel small molecule tubulin inhibitor STK899704
por: Sakchaisri, Krisada, et al.
Publicado: (2017)

New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and in silico study
por: Al-Sanea, Mohammad M., et al.
Publicado: (2023)

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
por: Li, Ning, et al.
Publicado: (2020)

Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition
por: Elmeligie, Salwa, et al.
Publicado: (2019)

The Design and Development of Potent Small Molecules as Anticancer Agents Targeting EGFR TK and Tubulin Polymerization
por: Ihmaid, Saleh, et al.
Publicado: (2018)

Synthetic Small Molecule Modulators of Hsp70 and Hsp40 Chaperones as Promising Anticancer Agents
por: Nitzsche, Bianca, et al.
Publicado: (2023)

Anticancer Small-Molecule Agents Targeting Eukaryotic Elongation Factor 1A: State of the Art
por: Zhang, Han, et al.
Publicado: (2023)

Hybrid cis-stilbene Molecules: Novel Anticancer Agents
por: Piekuś-Słomka, Natalia, et al.
Publicado: (2019)

Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274
por: Hou, Jinxuan, et al.
Publicado: (2011)

Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2020)

Small molecule KDM4s inhibitors as anti-cancer agents
por: Lin, Hongzhi, et al.
Publicado: (2018)

Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors
por: Zhao, Tong T., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_rmp759ggss28hii7qlent0nvvn